Palisade Bio Inc (PALI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $201.01M
Last updated: Nov 17, 2026 at 11:06 AM ET
Palisade Bio Inc (PALI) Earnings: Report Dates and Results
Palisade Bio (PALI) is expected to report earnings on Mar 18, 2027. In the quarter ended Sep 30, 2026, Palisade Bio reported EPS of -$0.07, below the -$0.06 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PALI has an expected report date of Mar 18, 2027.
Earnings History
Of the 24 quarters below that had an estimate, PALI beat 12, missed 11 and matched 1. The widest gap in the table came in the quarter ended Dec 31, 2022, when EPS landed 366.26% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.07 | -$0.06 | -$0.07 - -$0.05 | -16.67% | Miss | N/A | 8 | 1 up, 5 down | Nov 10, 2026 | N/A |
| Jun 30, 2026 | -$0.05 | -$0.05 | -$0.07 - -$0.04 | 0.00% | In line | N/A | 7 | 2 up, 1 down | Aug 10, 2026 | $500000 |
| Mar 31, 2026 | -$0.05 | -$0.04 | -$0.06 - -$0.01 | -14.50% | Miss | N/A | 6 | 0 up, 1 down | May 12, 2026 | N/A |
| Dec 31, 2025 | -$0.06 | -$0.03 | -$0.05 - -$0.01 | -97.17% | Miss | N/A | 6 | 1 up, 1 down | Mar 23, 2026 | N/A |
| Sep 30, 2025 | -$0.38 | -$0.27 | -$0.47 - -$0.03 | -40.74% | Miss | N/A | 3 | 1 up, 1 down | Nov 10, 2025 | N/A |
| Jun 30, 2025 | -$0.58 | -$0.56 | -$0.62 - -$0.48 | -3.57% | Miss | N/A | 3 | 0 up, 0 down | Aug 11, 2025 | N/A |
| Mar 31, 2025 | -$0.47 | -$0.81 | -$0.84 - -$0.78 | +41.98% | Beat | N/A | 2 | 0 up, 0 down | May 12, 2025 | N/A |
| Dec 31, 2024 | -$0.69 | -$1.99 | -$2.76 - -$0.81 | +65.27% | Beat | N/A | 3 | 0 up, 2 down | Mar 24, 2025 | $4000 |
| Sep 30, 2024 | -$2.32 | -$3.35 | -$3.63 - -$3.07 | +30.75% | Beat | N/A | 2 | 0 up, 0 down | Nov 12, 2024 | N/A |
| Jun 30, 2024 | -$3.32 | -$2.93 | -$3.11 - -$2.75 | -13.31% | Miss | N/A | 2 | 0 up, 0 down | Aug 12, 2024 | N/A |
| Mar 31, 2024 | -$4.59 | -$3.75 | N/A | -22.40% | Miss | N/A | 1 | 0 up, 0 down | May 13, 2024 | N/A |
| Dec 31, 2023 | -$6.45 | -$5.17 | -$5.40 - -$4.95 | -24.76% | Miss | -199.7% | 2 | 0 up, 0 down | Mar 26, 2024 | N/A |
| Sep 30, 2023 | -$7.35 | -$6.15 | N/A | -19.51% | Miss | N/A | 2 | 0 up, 0 down | Nov 9, 2023 | N/A |
| Jun 30, 2023 | -$7.95 | -$6.82 | -$7.50 - -$6.15 | -16.57% | Miss | N/A | 2 | 0 up, 0 down | Aug 11, 2023 | N/A |
| Mar 31, 2023 | -$8.10 | -$9.90 | -$11.84 - -$9.90 | +18.18% | Beat | N/A | 2 | 0 up, 0 down | May 12, 2023 | $250000 |
| Dec 31, 2022 | $6.47 | -$2.43 | -$2.47 - -$2.40 | +366.26% | Beat | N/A | 2 | 0 up, 0 down | Mar 22, 2023 | N/A |
| Sep 30, 2022 | -$61.06 | -$67.50 | N/A | +9.54% | Beat | N/A | 2 | 0 up, 0 down | Nov 14, 2022 | N/A |
| Jun 30, 2022 | -$90.00 | -$217.50 | N/A | +58.62% | Beat | N/A | 1 | 0 up, 0 down | Aug 15, 2022 | N/A |
| Mar 31, 2022 | -$13.00 | -$14.00 | -$14.50 - -$13.50 | +7.14% | Beat | N/A | 2 | 0 up, 0 down | May 13, 2022 | N/A |
| Dec 31, 2021 | -$165.75 | -$180.00 | N/A | +7.92% | Beat | N/A | 2 | 0 up, 0 down | Mar 16, 2022 | N/A |
| Sep 30, 2021 | -$187.27 | -$270.00 | N/A | +30.64% | Beat | N/A | 1 | 0 up, 0 down | Nov 15, 2021 | N/A |
| Jun 30, 2021 | -$3.53 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 24, 2021 | N/A |
| Mar 31, 2021 | -$4.39 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 14, 2021 | N/A |
| Dec 31, 2020 | -$0.25 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 22, 2021 | N/A |
| Sep 30, 2020 | -$4.39 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 10, 2020 | N/A |
| Jun 30, 2020 | -$4.39 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 13, 2020 | N/A |
| Mar 31, 2020 | -$4.39 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 15, 2020 | $6020 |
| Dec 31, 2019 | -$4.39 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 27, 2020 | $2500 |
| Sep 30, 2019 | -$4.39 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 14, 2019 | $2500 |
| Jun 30, 2019 | -$4.39 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 14, 2019 | $7894 |
| Mar 31, 2019 | -$0.22 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 14, 2019 | $2500 |
| Dec 31, 2018 | -$0.22 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 22, 2019 | $2500 |
| Sep 30, 2018 | -$0.12 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 14, 2018 | $2500 |
| Jun 30, 2018 | -$0.80 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 13, 2018 | $252500 |
| Mar 31, 2018 | -$2.80 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 2, 2018 | $2500 |
| Dec 31, 2017 | -$0.18 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 22, 2018 | $252500 |
| Sep 30, 2017 | -$0.18 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 8, 2017 | $2500 |
| Jun 30, 2017 | -$2,160.00 | -$4,380.00 | N/A | +50.68% | Beat | N/A | N/A | N/A | Aug 8, 2017 | $2500 |
| Mar 31, 2017 | -$2,580.00 | -$3,120.00 | N/A | +17.31% | Beat | N/A | N/A | N/A | May 10, 2017 | $2500 |
| Dec 31, 2016 | -$4,200.00 | -$3,120.00 | N/A | -34.62% | Miss | N/A | N/A | N/A | Mar 23, 2017 | $8746 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.49, after -$10.92 the year before. It was -$16,680.00 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.49 | N/A |
| Dec 31, 2024 | -$10.92 | N/A |
| Dec 31, 2023 | -$29.85 | N/A |
| Dec 31, 2022 | -$157.59 | N/A |
| Dec 31, 2021 | -$360.94 | N/A |
| Dec 31, 2020 | -$13.42 | N/A |
| Dec 31, 2019 | -$13.39 | N/A |
| Dec 31, 2018 | -$3.94 | N/A |
| Dec 31, 2017 | -$4,740.36 | N/A |
| Dec 31, 2016 | -$16,680.00 | N/A |
Frequently Asked Questions About PALI
When is Palisade Bio's next earnings date?
Palisade Bio's next earnings report is expected for Mar 18, 2027.
Did PALI beat earnings estimates last quarter?
No. Palisade Bio reported EPS of -$0.07 for the quarter ended Sep 30, 2026, below the -$0.06 estimate by 16.67%.
What EPS do analysts expect from PALI next quarter?
The consensus EPS estimate for Palisade Bio for the quarter ending Dec 31, 2026 is -$0.07 from 12 analysts, with estimates from -$0.10 to -$0.05.
How often does PALI beat earnings estimates?
Palisade Bio beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -8.18%.
PALI pages: Overview, Earnings, Forecast, Financials, Competitors